Forest sues would-be Savella copycats; U.K. health service rolls out Roche's sub-Q Herceptin;

@FiercePharma: Lundbeck's refusal to sell pentobarbital to prisons hits Ohio's execution plans. More from Reuters | Follow @FiercePharma

@EricPFierce: FDA warning letter for Strides Arcolab Agila Speciaities plant arrives. Mylan not too concerned. Story from FiercePharmaManufacturing | Follow @EricPFierce

> Forest Laboratories ($FRX) sued several generics makers for patent infringement over their plans to knock off the fibromyalgia drug Savella. Release

> The U.K.'s National Health Service adopted Roche's ($RHHBY) new injectable form of the HER2-positive breast cancer drug Herceptin. Report

> Par Pharmaceutical started shipping the new antidepressant Khedezla ER, a copycat version of Pfizer's ($PFE) Pristiq that isn't generically substitutable for the brand. Report

> Purdue Pharma won FDA approval for a new dosage strength of its Butrans Transdermal painkiller patch. Report

Medical Device News

@FierceMedDev: Biocept Laboratories becomes latest Dx outfit to explore IPO. ICYMI yesterday | Follow @FierceMedDev

@MarkHFierce: Medtronic won expanded indications for one of its key vascular stents. Release | Article | Follow @MarkHFierce

> Stryker inks $1.7B deal for Mako. News

> Tool to predict bad implant reactions shows potential. Item

> EnteroMedics slides after FDA squints at obesity device. Article

Biotech News

@FierceBiotech: The 2013 Fierce 15 biotech execs take a bow. Editor's corner | FierceBiotech's 2013 Fierce 15 | Follow @FierceBiotech

@JohnCFierce: Merck KGaA doubles down on Oncothyreon's failed cancer vaccine. Report | Follow @JohnCFierce

@DamianFierce: Apparently no one wanted to spend ~$3B on Clovis Oncology. Perhaps Big Pharma wants its biotechs to generate revenue. Story | Follow @DamianFierce

@EmilyMFierce: Stem cell reprogramming made easier by removing one protein. Popular yesterday from FierceBiotech Research | Follow @EmilyMFierce

> Infinity dumps lung cancer drug after PhII trial fails survival test. Article

> Plotting Asia expansion, Amgen blueprints plans for Shanghai research center. More

> Ophthotech, Foundation Medicine loot booming biotech IPO market for $273M. Article

Drug Delivery News

@MichaelGFierce: Laser-sensitive surface enables IV-drug identification for safer delivery. Story | Follow @MichaelGFierce

> Study: Artificial pancreas with inhaled insulin improves glucose control. More

> Alnylam heralds positive results for RNAi amyloidosis drug. Article

> Surefire collects $16.4M to expand cancer-drug catheter biz. Item

> Bind collects $70.5M IPO to support Accurin tech. Story

Diagnostics News

> Cognoptix Alzheimer's eye test generates robust trial results. Article

> Alzheimer's diagnosis may gain from PET imaging of tau proteins. Report

> Case Western, GSK find promise with MS diagnostic 'probe.' Story

> In vitro Dx to remain at top of med tech heap. More

> Cigna: Genetic counseling mandates will come for other Dx tests. Article

And Finally... The new federal health law is expected to cause a surge in patients seeking mental healtlh treatment. Report

Suggested Articles

Only months removed from a gamechanging label expansion for Vascepa, Amarin is scrambling after a district judge invalidated the drug's key patents.

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.